We are live on
!
Find out more
LWCFA
Loring Wolcott & Coolidge Fiduciary Advisors Portfolio holdings
AUM
$10.3B
1-Year Est. Return
3.26%
This Fund
S&P 500
This Quarter
Est. Return
+2.31%
1 Year Est. Return
+3.26%
3 Year Est. Return
+43.63%
5 Year Est. Return
+56.22%
10 Year Est. Return
+342.64%
AUM
$5.5B
AUM Growth
+$58M
(+1.1%)
Cap. Flow
-$11.2M
Cap. Flow
% of AUM
-0.2%
Top 10 Holdings %
Top 10 Hldgs %
36.95%
Holding
821
New
51
Increased
87
Reduced
185
Closed
82
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Becton Dickinson
BDX
|
+$25.4M |
| 2 |
Amazon
AMZN
|
+$17.1M |
| 3 |
Roper Technologies
ROP
|
+$14.2M |
| 4 |
TE Connectivity
TEL
|
+$12.1M |
| 5 |
Microsoft
MSFT
|
+$9.04M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
NVO
Novo Nordisk
NVO
|
+$11.6M |
| 2 |
TJX Companies
TJX
|
+$10.8M |
| 3 |
Johnson & Johnson
JNJ
|
+$8.91M |
| 4 |
Procter & Gamble
PG
|
+$8.9M |
| 5 |
Meta Platforms (Facebook)
META
|
+$8.24M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 27.8% |
| 2 | Healthcare | 17.78% |
| 3 | Financials | 10.19% |
| 4 | Consumer Staples | 9.56% |
| 5 | Consumer Discretionary | 9.32% |
Similar funds
VPIM
ACA
GI
RA
PF
RI
HRCM
HI
Loring Wolcott & Coolidge Fiduciary Advisors's Q1 2018 Portfolio in Review
As of Q1 2018, Loring Wolcott & Coolidge Fiduciary Advisors held 821 positions worth $5.5B, up 1.1% from $5.45B the previous quarter. Its ten largest holdings account for 37% of the portfolio.
Loring Wolcott & Coolidge Fiduciary Advisors's Q1 2018 filing shows 51 new, 87 increased, 185 reduced and 82 closed positions. Its largest new stake was Diamondback Energy: 3,285 shares worth $416K. The largest sale was Novo Nordisk, an estimated $11.6M.
By sector, the portfolio is most concentrated in Technology at 28% of assets, up from 26% a quarter earlier, followed by Healthcare and Financials.
- Loring Wolcott & Coolidge Fiduciary Advisors's largest Q1 2018 buy was Diamondback Energy: 3,285 shares worth $416K.
- Loring Wolcott & Coolidge Fiduciary Advisors added most to Becton Dickinson in Q1 2018, an estimated $25.4M increase.
- Loring Wolcott & Coolidge Fiduciary Advisors's biggest Q1 2018 reduction was Novo Nordisk, cutting an estimated $11.6M.
- Loring Wolcott & Coolidge Fiduciary Advisors fully exited Bioverativ Inc. Common Stock in Q1 2018, selling an estimated $229K.
- Loring Wolcott & Coolidge Fiduciary Advisors's ten largest holdings make up 37% of its $5.5B portfolio in Q1 2018.
- Loring Wolcott & Coolidge Fiduciary Advisors opened 51 new positions and closed 82 in Q1 2018.
- Loring Wolcott & Coolidge Fiduciary Advisors's portfolio value rose 1.1% quarter-over-quarter to $5.5B.
Based on Loring Wolcott & Coolidge Fiduciary Advisors's 13F filing for Q1 2018, filed 20 Apr 2018.